Stem Cell Theranostics and CapellaBio launch collaboration on cardiotoxicity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stem Cell Theranostics and CapellaBio established a cardio-oncology collaboration to discover novel drug therapies to prevent cardiotoxicity associated with various oncology drugs.

By combining CapellaBio’s SMarTR computational analysis platform with SCT’s iPSC-derived cardiomyocyte discovery platform, advanced drug leads have been identified in the first of a series of programs.

The first collaborative program is focused on discovering cardioprotective drugs to prevent anthracycline-induced cardiotoxicity. There is currently only one FDA-approved agent, Dexrazoxane, but this has limited indication approval and has not been widely used due to concerns that it may interfere with the anti-tumor activity of anthracyclines. Novel cardioprotectants with improved efficacy and safety profiles that could be used across multiple indications would offer significant clinical benefit.

Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login